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TGF-β induces miR-100 and miR-125b but blocks
let-7a through LIN28B controlling PDAC
progression
Silvia Ottaviani 1, Justin Stebbing1, Adam E. Frampton 2,3, Sladjana Zagorac1, Jonathan Krell3,
Alexander de Giorgio1, Sara M. Trabulo4,5, Van T.M. Nguyen1, Luca Magnani 1, Hugang Feng6,
Elisa Giovannetti7,8, Niccola Funel8, Thomas M. Gress9, Long R. Jiao2, Ylenia Lombardo1, Nicholas R. Lemoine10,
Christopher Heeschen4,5 & Leandro Castellano 1,11
TGF-β/Activin induces epithelial-to-mesenchymal transition and stemness in pancreatic
ductal adenocarcinoma (PDAC). However, the microRNAs (miRNAs) regulated during this
response have remained yet undetermined. Here, we show that TGF-β transcriptionally
induces MIR100HG lncRNA, containing miR-100, miR-125b and let-7a in its intron, via
SMAD2/3. Interestingly, we ﬁnd that although the pro-tumourigenic miR-100 and miR-125b
accordingly increase, the amount of anti-tumourigenic let-7a is unchanged, as TGF-β also
induces LIN28B inhibiting its maturation. Notably, we demonstrate that inactivation of miR-
125b or miR-100 affects the TGF-β-mediated response indicating that these miRNAs are
important TGF-β effectors. We integrate AGO2-RIP-seq with RNA-seq to identify the global
regulation exerted by these miRNAs in PDAC cells. Transcripts targeted by miR-125b and
miR-100 signiﬁcantly overlap and mainly inhibit p53 and cell–cell junctions’ pathways.
Together, we uncover that TGF-β induces an lncRNA, whose encoded miRNAs, miR-100, let-
7a and miR-125b play opposing roles in controlling PDAC tumourigenesis.
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Pancreatic ductal adenocarcinoma (PDAC) is a deadly dis-ease with a 5-year survival rate of ~6%1. PDAC has amalignant cell population comprising both proliferating
and cancer stem cells (CSCs)2,3. The majority of tumors (95%)
are driven by mutational hyper-activation of KRAS. Additional
characteristics include inactivation of TP53 (74%), P16/INK4A
(35%), SMAD4 (31%), and other TGF-β effectors4,5. TGF-β sig-
naling has a vital role in PDAC and other cancers6. It is released
from the inﬂammatory tumor microenvironment, and acts as
either a tumor suppressor or an oncogene, depending on cellular
context7,8. It activates SMAD2/3 transcription factors (TFs),
which in turn interact with SMAD4 to regulate the transcription
of a subset of genes9 that can differ depending on an individual
cell’s characteristics8. At some cell stages, TGF-β reduces cell
proliferation and increases apoptosis6. This effect can be impor-
tant for PDAC progression, because inactivation of TGF-β sig-
naling components in pancreatic precursor lesions, combined
with KRAS hyper-activation, induces PDAC formation and
metastasis10,11. In contrast, TGF-β family members can also
promote epithelial-to-mesenchymal transition (EMT), tumour-
igenesis and metastasis at more advanced stages of the
disease12,13.
We and others have demonstrated that miRNA dysregulation
plays a signiﬁcant role in PDAC tumourigenesis and progres-
sion14–19. Notably, miRNAs can be important in PDAC stemness
and EMT because ZEB1, a transcriptional repressor of CDH1,
also inhibits miR-200 family members, as well as miR-203, which
in turn repress several inducers of tumourigenesis17. Similar to
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Fig. 1 miR-100 and miR-125b expression is associated with EMT in PDAC cells. a In vitro cell line model of EMT spectrum. Phase-contrast images show
PDAC lines ordered from the most epithelial-like (left) to the most mesenchymal-like (right). Scale bar: 100 µm. b Immunoblot for E-cadherin (CDH1) in
PDAC cell lines with quantiﬁcation of CDH1/GAPDH ratio. c Heatmap showing selected up and down-regulated miRNAs from the nCounter expression
analysis. d Volcano plot displaying miR-100 and miR-125b being the most signiﬁcantly up-regulated miRNAs upon TGF-β treatment. e, f RT-qPCR for miR-
100 in e and miR-125b in f in PDAC lines. Values were normalized to RNU44 levels and are shown as mean ± s.e.m. Results are from three independent
experiments each performed in triplicate. **P-value < 0.01, ***P-value < 0.001. P-values were calculated using two-tailed Student’s t test
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miR-200s, the let-7 family of miRNAs induces reversion of EMT
in Gemcitabine (GEM)-resistant PDAC cells20. Interestingly,
LIN28B has been shown to inhibit the biogenesis of let-7 family
members, enhancing the progression of PDAC and other
cancers21,22. In contrast to miR-200 and let-7 family members,
miR-100 and miR-125b are up-regulated in GEM-resistant cells
and promote EMT in PDAC23–25.
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Remarkably, the miRNAs regulated by TGF-β in PDAC have
remained undetermined.
Here, we show that TGF-β increases MIR100HG transcription
through SMAD2/3. The induction of LIN28B in the same TGF-β
response results in the up-regulation of miR-100 and miR-125b,
with let-7a unchanged despite being part of the same MIR100HG
primary transcript. We also show that these miRNAs regulate a
multitude of genes involved in the inhibition of p53 and DNA
damage response pathways, which are crucial for the progression
of this frequently metastatic disease. Considering that targeting
miRNAs could be used for anti-cancer therapy (reviewed in
ref. 26), the inhibition of miR-125b and/or miR-100 in patients
could be considered as a new therapeutic approach for treating
PDAC, and also as biomarkers for stratifying PDAC.
Results
TGF-β treatment induces miR-100 and miR-125b. To discover
novel miRNAs implicated in PDAC progression through TGF-β,
we created an in vitro cellular model with cell lines positioned
along a gradient moving from epithelial-like to mesenchymal-like
status, including cells treated with TGF-β (Fig. 1a), and per-
formed nCounter miRNA expression proﬁling (Supplementary
Data 1). Speciﬁcally, we used epithelial-like BxPC-3 cells; PANC-
1 cells that are part-epithelial, part-mesenchymal-like; PANC-1
treated with TGF-β that adopt a more spindle-shaped,
mesenchymal-like morphology and ﬁnally highly invasive/meta-
static S2-007 PDAC cells (Fig. 1a). As expected, the expression
levels of CDH1 were inversely correlated with the mesenchymal-
like status of the cells (Fig. 1b). Additionally, we conﬁrmed that
miR-200 family members were strongly down-regulated in
mesenchymal-like cells compared to BxPC-3 epithelial-like cells
(Fig. 1c and Supplementary Data 1), as previously shown17,20.
Surprisingly, the expression of this family of miRNAs did not
change upon TGF-β treatment in PANC-1 (Fig. 1c and Supple-
mentary Data 1), indicating that they are not part of the TGF-β
regulated EMT response in PDAC. Only two miRNAs, namely
miR-100 and miR-125b, increased proportionally with the
mesenchymal status of the cell (Fig. 1c and Supplementary
Data 1), and were signiﬁcantly up-regulated by TGF-β (adjusted
P < 0.01, Wald Test) (Fig. 1c, d and Supplementary Data 1). We
validated this result by RT-qPCR (Fig. 1e,f). Moreover, the
expression of both miR-100 and miR-125b was signiﬁcantly
higher in PANC-1 stably overexpressing TGF-β27 compared to
PANC-1 stably transfected with empty vector, whilst the levels of
miR-200 remained unchanged (Supplementary Fig. 1a), inde-
pendently conﬁrming our ﬁndings.
TGF-β increases MIR100HG transcription through SMAD2/3.
Next, we treated PANC-1 cells with TGF-β and performed RNA-
sequencing (RNA-seq) to evaluate how the TGF-β-mediated
increase of miR-100 and miR-125b relates to the mRNA reg-
ulation exerted by the same stimulus (Supplementary Fig. 1b and
Supplementary Data 2). As expected, TGF-β signiﬁcantly up-
regulated pro-EMT factors, such as SNAI1, SNAI2, and CDH2,
and down-regulated the cell–cell junction protein CDH1
(adjusted P < 0.05, Wald Test, Supplementary Fig. 1c and Sup-
plementary Data 2), supporting the validity of our approach.
Interestingly, MIR100HG, a long noncoding RNA (lncRNA) and
also the tricistronic host gene of miR-100, miR-125b, and let-7a
(Supplementary Fig. 2a), was amongst the RNAs signiﬁcantly up-
regulated by TGF-β treatment (adjusted P < 0.01, Wald Test)
(Fig. 2a and Supplementary Data 2), indicating transcriptional
induction of miR-100 and miR-125b by TGF-β. Accordingly,
miR-100 and miR-125b precursors (pre-miR-100 and pre-miR-
125b) show a similar pattern of regulation as their mature
miRNA forms (Supplementary Fig. 2b). Subsequently, we per-
formed SMAD2/3 chromatin immunoprecipitation sequencing
(ChIP-seq) following TGF-β treatment in PANC-1 cells. Regions
within 20 kilobases from the transcription start sites (TSSs) of
TGF-β up-regulated genes were enriched in SMAD2/3 interaction
sites (2.9 fold; P < 0.0001, Fisher’s exact test) (Supplementary
Fig. 2c), indicating that TGF-β regulates several genes through its
canonical pathway during EMT in PANC-1 cells. ChIP-seq of
SMAD2/3 in both human (Fig. 2a and Supplementary Fig. 3b)
and mouse PDAC cells7 (Supplementary Fig. 2d) indicated that
these TFs interact with several regions located along the
MIR100HG gene, and have the strongest interactions in proxi-
mity to the TSS of the annotated (RefSeq) MIR100HG transcript
(Fig. 2a and Supplementary Fig. 3b). Accordingly, the down-
regulation of SMAD2 and SMAD3 using speciﬁc siRNAs (Sup-
plementary Fig. 2e) signiﬁcantly reduced miR-100 and miR-125b
levels, and totally impaired the ability of TGF-β to increase their
abundance (Supplementary Fig. 2f). In addition, MIR100HG
represents the only regulated transcript by TGF-β located within
its related topological associated domain (TAD) (Supplementary
Fig. 3a), indicating that SMAD2/3 interact here to speciﬁcally
increase MIR100HG transcription. Interestingly in mice PDAC
cells, SMAD2/3 interaction was reduced in SMAD4 (−) cells
(Supplementary Fig. 2d). Accordingly, SMAD4 has been shown
to be important for the regulation of EMT-related genes7. We
additionally validated the direct SMAD2/3 interaction with the
MIR100HG promoter in both COLO357 and PANC-1 PDAC
cells by ChIP-qPCR (Supplementary Fig. 2g). Interestingly,
MIR100HG transcript appears to have at least three TSSs, as
demonstrated by the presence of two additional H3K27ac and
H3K4me3 peaks downstream of the annotated TSS (Supple-
mentary Fig. 3b). In order to elucidate transcriptional regulation
of MIR100HG by TGF-β, we used CRISPR-Cas9 to remove the
ﬁrst TSS containing the strongest SMAD2/3 interactions (Sup-
plementary Fig. 3b). Although this deletion signiﬁcantly reduced
MIR100HG, as well as miR-100 and miR-125b expression (Sup-
plementary Fig. 3c), it did not impede the ability of TGF-β to
increase their levels (Supplementary Fig. 3d), suggesting the
intriguing possibility that SMAD2/3 may use other sites more
intensively to regulate MIR100HG expression, in the absence of
the main ones. In aggregate, these ﬁndings suggest that TGF-β
activates SMAD2/3, which in turn directly regulates the tran-
scription of a gene network which includes MIR100HG, along
with miR-100 and miR-125b, thereby promoting EMT and
tumourigenesis in PDAC cells.
Fig. 2 TGF-β induces miR-100 and miR-125b but not let-7a by co-regulation of MIR100HG and LIN28B. a Top: integrative genomics viewer (IGV) tracks
show up-regulation of MIR100HG transcript in PANC-1 cells treated with TGF-β for 72 h compared to vehicle control as determined by RNA-seq (n= 3 for
each condition). Bottom: IGV tracks show SMAD2/3 binding to MIR100HG locus in cells treated with TGF-β for 1 h as determined by ChiP-seq (n= 2 for
TGF-β treated samples and n= 1 for input sample). b RT-qPCR of miR-100, miR-125b, let-7a normalized to RNU44 levels (left), LIN28B normalized to
GAPDH levels (right) and Immunoblot for LIN28B and β-ACTIN (bottom-right) in PANC-1 cells treated with TGF-β for the indicated time points. c RT-qPCR
of miR-100, miR-125b and let-7a normalized to RNU44 levels in human PDAC COLO357 and CHX45 cells (derived from a KPC mouse model), after
treatment with TGF-β for 72 h. In b, c values represent the mean ± s.e.m. Results are from three independent experiments each performed in triplicate. *P-
value < 0.05, **P-value < 0.01, ***P-value < 0.001. P-values were calculated using two-tailed Student’s t test. d–i Pearson correlation analyses in PDAC
samples derived from TCGA-PAAD (n= 183)
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TGF-β induces miR-100 and miR-125b, but blocks let-7a. It has
been shown that let-7 family members reduce tumourigenesis in
PDAC28 and other cancers29,30. Since TGF-β and other family
members13 act to increase pancreatic tumourigenesis, any rise in
let-7a levels following MIR100HG induction as part of this
response would serve to counteract this effect. In fact, despite the
TGF-β-mediated increase in MIR100HG transcription, which
augments miR-100 and miR-125b levels (Figs 1c–f and 2a, Sup-
plementary Data 1-2), 72 h of TGF-β treatment did not sig-
niﬁcantly up-regulate either let-7a or other let-7 family members
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in PANC-1 cells (Supplementary Data 1). Conversely, we noticed
a slight TGF-β-mediated decrease of let-7b expression (Supple-
mentary Data 1, adjusted P= 0.08, Wald Test). This suggests that
let-7a is repressed at the post-transcriptional level by another
TGF-β-regulated factor, thereby remaining unchanged during the
response. To identify the mechanism of let-7a regulation we
interrogated our RNA-seq data to see if factors known to regulate
let-7 biogenesis (reviewed in ref.31) were modulated by TGF-β
(Supplementary Data 2). Strikingly, LIN28B, implicated in the
post-transcriptional inhibition of let-7 maturation21,32, was sig-
niﬁcantly induced by TGF-β (Supplementary Data 2, adjusted
P < 0.01, Wald Test). This suggested that while LIN28B and
MIR100HG are both induced by TGF-β, with miR-100 and miR-
125b levels increasing, let-7a levels remain low due to post-
transcriptional repression by LIN28B. In fact, LIN28B up-
regulation has been shown to decrease let-7 levels, and increase
let-7 targets during PDAC progression22. Accordingly, silencing
of LIN28B by RNA interference in PANC-1 cells increased let-7a,
but not miR-100 and miR-125b expression (Supplementary
Fig. 4a). Likewise, we noticed that PANC3.27 cells treated with
shRNAs against LIN28B22 resulted in increased let-7a, but not
miR-125b or miR-100 levels. To evaluate the kinetics of LIN28B/
let-7a regulation during the TGF-β response, we performed a
time course experiment following TGF-β treatment, and mea-
sured miR-100, miR-125b, let-7a levels (Fig. 2b left panel), as well
as both LIN28B mRNA (Fig. 2b top-right panel) and protein
(Fig. 2b bottom-right panel) levels. Strikingly, while 3 h of TGF-β
treatment induced both miR-100 and miR-125b expression,
which progressively increased from 3 to 72 h (Fig. 2b left panel),
let-7a levels signiﬁcantly rose from 3 to 6 h, but then returned to
untreated levels once LIN28B started accumulating at 6 h
(Fig. 2b). Conversely, TGF-β signiﬁcantly increased let-7a along
with miR-100 and miR-125b in two additional TGF-β responsive
(Supplementary Fig. 4b) PDAC cells, human COLO357 and
mouse CHX45 (isolated from KPC mice by Hermann and col-
leagues33) (Fig. 2c), in which LIN28B levels were almost unde-
tectable (Supplementary Fig 4c). Finally, the capacity of TGF-β to
increase the levels of let-7a was restored in multiple PANC-1
cellular clones knocked-out (KO) for LIN28B generated by
CRISPR-Cas9 (Supplementary Fig. 4d). LIN28A, homologous
protein of LIN28B was never expressed or induced by TGF-β in
these cells (Supplementary Fig. 4e), excluding its involvement in this
process. Notably, miR-100 and miR-125b expression were closely
correlated in 183 PDAC samples derived from The Cancer Genome
Atlas (TCGA) (r= 0.8, P < 2.2e-16, Pearson correlation test), indi-
cating that these two miRNAs are usually co-expressed in PDAC
(Fig. 2d). Although neither miR-100 nor miR-125b was correlated
with let-7a (Fig. 2e, f), the correlation of miR-100 or miR-125b with
let-7a increased and became signiﬁcant when assessed only in
PDACs expressing low levels of LIN28B (Fig. 2h, i).
Interestingly, in contrast to SMAD4 (+) cells (PANC-1,
COLO357 and CHX45) (Fig. 2b, c), TGF-β was unable to induce
either miR-100 or miR-125b levels in SMAD4 (−) cells (BxPC-3
and S2-007) (Supplementary Fig. 4f), indicating that SMAD4 is
crucial for MIR100HG induction.
In aggregate, these data indicated that TGF-β-SMADs-
signaling induces MIR100HG and the miRNAs contained within
it, but later also induces LIN28B to reduce let-7a levels in order to
enhance the TGF-β response.
miR-100 and miR-125b control PDAC progression. To evaluate
whether miR-125b and miR-100 regulate EMT, tumourigenesis
and metastasis, we overexpressed both miRNAs in BxPC-3,
PANC-1, and mouse CHX45 cells, and assessed both cell mor-
phology (Fig. 3a) and levels of EMT markers (Supplementary
Fig. 5a). Overexpression of each miRNA produced more spindle-
shaped cells than cells transfected with miRNA negative control
(n.c.), a characteristic of mesenchymal cell types (Fig. 3a), thus
conﬁrming previous ﬁndings23. While both miRNAs may sti-
mulate EMT in these cells, the effect of miR-125b seemed more
marked (Fig. 3a). Both miRNAs may act by elevating the
expression of the mesenchymal marker VIM, but without sig-
niﬁcantly reducing CDH1 levels (Supplementary Fig. 5a). Despite
this, immunoﬂuorescent experiments revealed that cell–cell
interaction was impaired. We observed that miR-100 induced
disruption of CDH1 at the level of cell–cell junctions (Fig. 3b),
while miR-125b promoted a complete CDH1 and actin deloca-
lization from the junctions (Fig. 3b). Next, we stably impaired the
activity of miR-100 or miR-125b using miRZip technology in
metastatic/mesenchymal-like S2-007 cells expressing high levels
of both miRNAs (Supplementary Data 1). In contrast to over-
expression experiments (Fig. 3a,b), clones of S2-007 stable cell
lines (Z100-3, Z100-4, Z125b-5, Z125b-3) with reduced miR-100
or miR-125b activity adopt remarkable epithelial-like morphol-
ogies (Fig. 3c). Additionally, mesenchymal markers such as VIM,
ZEB1, and SNAI1 were signiﬁcantly reduced (Supplementary
Fig. 5b). This suggested that inhibition of these miRNAs in
mesenchymal-like PDAC cells could promote mesenchymal to
epithelial transition (MET), independent of CDH1 levels.
It is known that EMT forms cells that are more motile and
metastatic17. Wound-healing scratch assays, followed by video
tracking of cell movements, showed that S2-007 cells stably
knocked down for miR-100 or miR-125b (Supplementary Fig. 5c
and Supplementary Movies 1–3), as well as LPC006 and LPC067
primary PDAC cultures transfected with anti-miR-100 and anti-
miR-125b (Supplementary Fig. 5d–g), displayed a strong reduc-
tion in cell migration compared to controls. Moreover, S2-007
cells with impaired miR-125b activity had markedly reduced
colonization of mice livers (i.e. metastatic spread), whilst S2-007
Fig. 3 Effects of miR-100 and miR-125b on EMT and stemness. a Phase-contrast images of BxPC-3, PANC-1, and CHX45 cells treated with control mimic
(pre-nc) or mature miRNA mimics (pre-miRs) for 12 days (5 nM). Scale bar: 100 µm. b Immunoﬂuorescence (IF) staining for CDH1 (red) and F-actin
(green) in BxPC-3 treated as in a. Nuclei are visualized with TO-PRO-3 stain (blue); scale bar: 20 µm. In a, b representative images from three independent
experiments are shown. c Morphology of S2-007 stable knockdown clones for miR-100 (Z100), miR-125 (Z125b), and control (Zc) generated with Zip
technology. Representative pictures from two different clones per treatment are shown. Phase-contrast images are shown at the top and corresponding
GFP images at the bottom. Scale bar: 400 µm. d–f Sphere-forming assays in BxPC-3 cells transiently transfected with precursor miRNA mimics (d), in
PANC-1 cells treated with anti-miRNA inhibitors (e), and in four independent PANC-1 Zip stable knockdown clones (n= 4) (f). Representative spheres are
shown in lower panels in phase-contrast images and corresponding GFP images. Values represent the mean ± s.e.m. Data are from three independent
experiments each performed in triplicate. g Mice were subcutaneously injected with the indicated number of S2-007 Zip control cells (Zc-11) on the right
ﬂank and S2-007 Zip stable miR-100 knockdown (Z100-3) or miR-125b knockdown (Z125b-5) on the left ﬂank (n= 5 per group). Tumor take was
determined 3 weeks post-injection. Cancer stem cell (CSC) frequencies were calculated using the extreme limiting dilution analysis algorithm (http://
bioinf.wehi.edu.au/software/elda/). h Images of resected tumors are shown. **P-value < 0.01, ***P-value < 0.001. P-values were calculated using two-
tailed Student’s t test
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cells with impaired miR-100 activity were less effective (Supple-
mentary Fig. 6a, b).
Furthermore, it has been demonstrated that EMT can generate
cells with properties of stem cells, which are highly tumourigenic
and metastatic, as well as resistant to chemotherapy17,34. In
addition, TGF-β family members induce both EMT and
stemness13,35. This suggests that TGF-β may increase miR-100
and miR-125b expression to promote both EMT and
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tumourigenesis in PDAC. To test this hypothesis, we performed
tumor-sphere formation assays13,36 after manipulation of miR-
100 or miR-125b activity. Overexpression of miR-100 or miR-
125b in BxPC-3 cells, which have low levels of these two miRNAs
(Supplementary Data 1), signiﬁcantly increased the number of
tumor spheres (Fig. 3d). Conversely, inhibition of miR-100 or
miR-125b with anti-miRNAs in PANC-1 cells, reduced tumor
spheres compared to anti-miRNA-n.c. transfected cells (Fig. 3e).
Moreover, independent PANC-1 clones with stably impaired
activity of miR-100 or miR-125b by miRZip had reduced capacity
to form tumor spheres, compared to clones infected with vector
controls (Fig. 3f). We were unable to develop individually stable
tumor spheres in culture using S2-007 cells, supporting the
notion that highly mesenchymal cells deﬁcient in cell–cell
adhesion may fail to form reliable tumor spheres37. As an
alternative, we assessed expression levels of CD133, an established
and speciﬁc marker for evaluation of pancreatic CSC
enrichment13,14. We demonstrated that S2-007 clones with
impaired activity of miR-100 or miR-125b expressed signiﬁcantly
lower levels of CD133 (Supplementary Fig. 6c, d). Pancreatic
CSCs are notoriously resistant to GEM13, indicating that
treatments aiming to remove this population in conjunction
with GEM have the potential to be an effective adjuvant PDAC
therapy13.
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We conﬁrmed that, similarly to established PDAC cell lines23,25,
anti-miR-100 and anti-miR-125b signiﬁcantly sensitized two
different primary PDAC cell cultures, derived from laser-
microdissected PDAC specimens (LPC006 and LPC067), to
apoptosis upon GEM treatment (Supplementary Fig. 6e), indicat-
ing that these miRNA inhibitors could be clinically useful.
To assess whether miR-100 and miR-125b regulate tumor-
initiating capacity of PDAC cells, we performed serial dilution
assays in nude mice with S2-007 cells stably knocked down for
miR-100, miR-125b, or empty vector control (Fig. 3g, h).
Accordingly, these knockdown clones showed a strong reduction
in their in vivo tumor-initiating capacity (Fig. 3g, h). Moreover,
even when these knockdown cells formed tumor xenografts, they
were signiﬁcantly smaller than empty vector controls (Fig. 3h).
miR-100 and miR-125b are required for TGF-β cell responses.
We next assessed whether miR-100 and miR-125b were critical
for TGF-β-induced tumourigenesis. Remarkably, TGF-β-
mediated increase in tumor-sphere formation was reverted
in vitro, in independent PANC-1 KO clones for miR-125b, gen-
erated by CRISPR-Cas9 (Fig. 4a, b and Supplementary Fig. 7b, d),
but was only partially reduced in clones KO for miR-100 (Fig. 4a,
b and Supplementary Fig. 7a, c). We observed a similar effect
performing in vivo tumourigenic assays using PANC-1 clones
with reduced miR-100 and miR-125b activity (Zip clones), with
or without TGF-β stable overexpression (Supplementary Fig. 8a).
This indicated that miR-125b is essential for TGF-β induced
tumourigenesis in PDAC, and represents the most important
TGF-β effector amongst the miRNAs derived from MIR100HG.
Importantly, the ability of TGF-β to increase motility (Fig. 4c,
d) or formation of spindle-shaped cells (Fig. 4e) was strongly
inhibited in the PANC-1 CRISPR-Cas9 clones that were KO for
miR-100 and miR-125b. In addition, transient inhibition of both
miR-100 and miR-125b negatively affected the capacity of TGF-β
to induce the formation of spindle-shaped cells (Supplementary
Fig. 8b), or to increase cell motility (Supplementary Fig. 8c) in
PANC-1 cells stably overexpressing TGF-β or empty vector
control.
Clinical relevance of miR-100 and miR-125b. Next, we assessed
miR-100 and miR-125b expression in PDAC tissues, by com-
bining data from multiple studies (Supplementary Table 1). This
analysis showed that both miRNAs are signiﬁcantly up-regulated
in independent cohorts of PDAC samples versus normal pancreas
(NP; miR-125b, PDAC= 343, Normal= 173; miR-100, PDAC=
258, Normal= 129) (Supplementary Table 1). We also used our
collection of laser-microdissected samples and measured CDH1,
SNAI1 as well as miR-125b and miR-100 using RT-qPCR
(Fig. 5a–c). This revealed that CDH1 expression is decreased in
PDAC compared to NP samples, but in lymph-node (LN)
metastases increase to the levels present in NP, suggesting that LN
metastatic cells may have undergone MET (Fig. 5a). In contrast,
both miR-100 and miR-125b were signiﬁcantly up-regulated in
PDAC, but in LN metastases decrease to the levels present in NP
(Fig. 5b). This suggests that their expression is down-regulated as
part of a shift towards a more epithelial-like phenotype as cells
establish within the LN. Interestingly, high expression of miR-100
and miR-125b was associated with worse overall-survival (OS)
after surgical resection (Fig. 5c). Next, we evaluated whether OS
was only associated with miRNA expression in tumor cells, or
whether expression in surrounding stroma could also be impor-
tant. To investigate this, we performed in situ hybridization (ISH)
for miR-100 and miR-125b on an independent collection of
PDAC samples (n= 100; all Stage IIB) and quantiﬁed miRNA
expression intensity (Fig. 5d, e). Whilst high miR-100 and miR-
125b levels in tumor cells were associated with both reduced OS
(Fig. 5f) and reduced disease-free survival (DFS) (Fig. 5g) after
resection, there was no signiﬁcant association between stromal
expression and prognosis (Fig. 5h). Moreover, we found that
poorly differentiated (high grade) tumors were associated with
high miR-125b (P= 0.042), but not high miR-100 tumoural
expression (Supplementary Table 2).
RIP-USE globally identiﬁes miR-100 and miR-125b targets.
Our results indicated that these two TGF-β-regulated miRNAs
are involved in several overlapping phenotypes that could be
explained by the regulation of multiple targets. To identify the
targets post-transcriptionally regulated by them in PDAC, we
developed a novel approach to integrate miRNA overexpression
with AGO2 RNA immunoprecipitation (RIP) sequencing (RIP-
seq) and differential expression analysis within a bioinformatics
framework with Sylamer and cWords algorithms38–40. We called
this method RIP followed by Unbiased Sequence Enrichment
analysis (RIP-USE) (Fig. 6a and Methods). This method is
developed in several steps (Fig. 6), including overexpression or
down-regulation of the miRNA of interest in cell lines, followed
by AGO2-RIP-seq and RNA-seq of total RNA to reveal both
transcripts that are signiﬁcantly enriched (in the case of miRNA
overexpression), or depleted (in the case of miRNA inhibition)
from AGO2, and are functionally repressed by the
miRNA–AGO2–target interaction. This is followed by unbiased
seed enrichment analysis to identify ribonucleotide regions of
miRNA–transcript interaction (Fig. 6). Since miR-100 and miR-
125b were both up-regulated about 40-fold in our highly
mesenchymal-like S2-007 cells, compared to the most epithelial-
like and less tumourigenic BxPC-3 cells (Fig. 1e, f and Supple-
mentary Data 1), we took this degree of up-regulation to repre-
sent a physiologically appropriate range for bridging the EMT
spectrum, such that 40-fold overexpression in the TGF-β PANC-
1 cells could enable us to identify relevant targets of a miRNA-
induced EMT. To this end, we chose the concentration of mimics
that increased the cellular miRNA levels by about 40-fold (Sup-
plementary Fig. 9a, b) and performed RIP-USE (Fig. 6a). As
expected, 3′UTRs of transcripts that were loaded onto AGO2
after miR-125b or miR-100 overexpression (Supplementary
Data 3) were also strongly enriched with miR-100 or miR-
125b “seed” motifs (Supplementary Fig. 9c–h). Consistently,
cWords showed similar results to Sylamer (Supplementary Fig. 9i,
j).
Interestingly, words of nucleotides enriched for miR-100
targets also included U rich motifs (URMs) (Supplementary
Fig. 9j), indicating that additional RNA-binding proteins may be
important during miR-100 regulation, as has been shown for
other miRNAs39. To test whether the motifs identiﬁed as
interacting with AGO2-loaded miRNAs (Supplementary
Fig. 9c–j) also inhibit the expression of those genes, we performed
cumulative distribution analysis using RNA-seq data obtained
following miR-100 or miR-125b overexpression. As expected,
transcripts containing 8mer, 7mer-m8, 7mer-1A as well as 6mer
seeds were signiﬁcantly down-regulated compared to transcripts
lacking these motifs, thus conﬁrming that interaction of AGO2
with these sites in the 3′UTRs down-regulates the targets in our
system (Fig. 6b, c). Transcripts containing 8mer and 7mer-m8
motifs were more greatly suppressed than targets with 7mer-1A
and 6mer sites (Fig. 6b, c), conﬁrming previous ﬁndings41.
Seeds for miR-100 have been depleted during evolution. To
evaluate the molecular pathways regulated by the targets of miR-
100 and miR-125b in PDAC, we considered the list of genes
overlapping between transcripts loaded onto AGO2 and genes
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Fig. 7 miR-100 and miR-125b target similar transcripts to regulate common pathways. a, b Venn diagrams showing miR-125b (a) or miR-100 (b) direct
targets represented as overlap of the top 4000 transcripts most enriched onto AGO2 from RIP-seq (RIP) and the top 1300 down-regulated transcripts in
RNA-seq (DW), after miRNA overexpression. The bar charts indicate the statistical signiﬁcance of the overlap between the two groups. P-values were
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the overlap between RIP and DW were used as input for the analysis. The threshold of signiﬁcance is indicated by the intermitted line. Positive Z-score
(red) indicates that the canonical pathway is activated and negative Z-score (blue) that is inhibited, based on the expression values in the data set. e, f Sub-
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down-regulated following miRNA overexpression, to select for
directly regulated targets. GSEA analysis of genes down-regulated
by miR-125b or miR-100 overexpression (RNA-seq) showed the
highest density of 7mer-m8 interacting motifs in the top 1300
down-regulated genes (Supplementary Fig. 10a, b),
whereas AGO2-transcripts enrichment analysis upon miR-125b
or miR-100 overexpression (RIP-seq) found the highest density of
7mer-m8 interacting sites in the top 4000 most AGO2-loaded
transcripts (Supplementary Fig. 10c, d). The overlaps between
genes enriched onto AGO2, and genes down-regulated after
miRNA overexpression were over 3-fold higher than expected by
chance (P < 2.2e-16, exact hypergeometric probability) for both
miRNAs (Fig. 7a, b), conﬁrming that these fractions are strongly
enriched for directly regulated targets. We next validated miRNA-
target regulation using both luciferase reporter assays and eval-
uated their expression levels in PANC-1 clones with impaired
activity for each miRNA, selecting important modulators of the
observed phenotypes (Supplementary Fig. 10e–h). MiRNA
recognition sites for miR-100 were much fewer than the sites
recognized by miR-125b (Supplementary Fig. 10a–d). This was
because the number of miR-125b seeds located in all transcripts
were higher than the null expectation of randomly generated 7
and 8mers, whereas the number of seeds for miR-100 was con-
siderably lower than that null expectation (Supplementary
Fig. 11a). This indicates that although miR-125b seeds in tran-
scripts have been gained during evolution, miR-100 consensus
sites have been depleted. Despite this remarkable difference, the
number of genes that overlap between RIP and down-regulated
transcripts were highly comparable (Fig. 7a, b), suggesting that
miR-100 interacts with AGO2 to regulate targets in a way that is
not explainable by seed base-pairing. Accordingly, CLASH42
analysis of miR-100 and miR-125b-target chimeras showed that
only 13% of the targets recognized by miR-125b are not explained
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by seed complementarity, whereas this percentage rose to 71% for
miR-100 (Supplementary Fig. 11b).
miR-100 and miR-125b regulate common pathways in PDAC.
Ingenuity Pathway Analysis (IPA) of genes enriched for direct
targets of miR-100 and miR-125b (Fig. 7a, b) showed that these
two miRNAs regulate similar pathways ranging from
p53 signaling, DNA repair and apoptosis (Fig. 7c–f), all of which
are crucial for PDAC progression and metastasis1. Activation Z-
score IPA values indicated that miR-125b signiﬁcantly down-
regulates p53 pathway, apoptosis and CHK proteins in cell cycle
checkpoints in response to DNA damage, whereas miR-100
mainly down-regulates CHK proteins in cell cycle checkpoints in
response to DNA damage, but also p53 and BRCA1 DNA repair
signaling and apoptosis (Fig. 7c, d). Accordingly, the overlap
between the transcripts regulated by both miRNAs was very
signiﬁcant and over 7-fold higher than expected by chance
(P < 2.2e-16, exact hypergeometric probability) (Supplementary
Fig. 11c). Targeting many of the same transcripts gives these
miRNAs additional regulatory power, providing a means for
double-bound targets to be more strongly repressed than others
in order to maintain an integrated cellular response41. We sum-
marized the interactions based on RIP-USE results (Fig. 6),
between these miRNAs and the genes belonging to these path-
ways (Fig. 7e,f and Supplementary Data 4).
To evaluate the nature of the perturbations exerted by miR-100
or miR-125b, we selected both up- and down-regulated genes
derived from the overexpression of each of these miRNAs (Z-
score <−1.5 and Z-score > 1.5, Supplementary Data 5) and
performed separate IPA analyses (Supplementary Fig. 11d,e and
Supplementary Data 6). Combining the effects of these two
miRNAs, we again showed that both signiﬁcantly regulate
common pathways, with the most important being CHK proteins
in cell cycle checkpoints in response to DNA damage,
p53 signaling, and apoptosis (Supplementary Fig. 11d and
Supplementary Data 6). Comparison analysis combined with
IPA Z-score values indicated that both miRNAs strongly down-
regulate p38 MAPK, PTEN, p53 signaling, and apoptosis, yet up-
regulate PI3K-AKT signaling and actin nucleation by
ARP–WASP complex (Supplementary Fig. 11e and Supplemen-
tary Data 6), providing a rationale for why PDAC cells
overexpressing these two miRNAs become more motile.
miR-100 and miR-125b targets are repressed in mesenchymal
cells. Remarkably, the epithelial BxPC-3 cells express low
amounts of miR-100 and miR-125b, whereas the mesenchymal-
like metastatic S2-007 cells express very high levels (Supple-
mentary Data 7). In fact miR-100 and miR-125b are the highest
expressed miRNAs in S2-007, indicating that they are important
drivers of PDAC aggressiveness. To demonstrate the impact of
this change in expression, we performed RNA-seq of BxPC-3 and
S2-007 (Supplementary Data 8). Notably, transcripts down-
regulated in S2-007 versus Bx-PC3 cells were signiﬁcantly enri-
ched in miR-125b and miR-100 targets (Supplementary Fig. 12a,
b). We found that 123 genes with seeds for miR-125b were down-
regulated in S2-007 cells and overlapped with genes regulated by
miR-125b in PANC-1 cells (Fig. 7a and Supplementary Fig. 12c).
These 123 genes were still enriched for apoptosis, tight junction,
and p53 pathways (Supplementary Fig. 12d). The number of
overlapped genes for miR-100 with seeds was too low to have a
reliable pathway enrichment analysis, probably due to the low
amount of these consensus sites in the human transcriptome
(Supplementary Fig. 10b, d and Supplementary Fig. 11a).
Discussion
TGF-β can promote EMT by inducing SNAI1 and ZEB1/2, which
in turn repress the transcription of the adherent junction gene
CDH16. Remarkably the miRNAs regulated during the TGF-β
response in PDAC were previously unknown.
Herein, we show that TGF-β, via SMAD TFs, induces tran-
scription of MIR100HG, which derives miR-100, let-7a, and miR-
125b, but surprisingly only miR-100 and miR-125b are up-
regulated (Fig. 8).
Remarkably, we found that inhibition of miR-125b or miR-100
affects the ability of TGF-β to induce cell motility, and the
capacity of TGF-β to promote spindle-shaped cells, indicating
that these miRNAs are important effectors of TGF-β. Interest-
ingly, only miR-125b reverts the capacity of TGF-β induced
tumourigenesis in vitro and in vivo, suggesting that miR-125b
represents the most important effector of TGF-β-mediated
tumourigenesis from those produced by MIR100HG. The lack
of let-7a stimulation appears to result from TGF-β’s induction of
LIN28B which post-transcriptionally down-regulates let-7a levels
(Fig. 8). To the best of our knowledge, a similar system that
includes the up-regulation of a primary multi-cistronic miRNA-
transcript, followed by the post-transcriptional inhibition of
speciﬁc miRNAs within it, has not been demonstrated before, and
we propose here that such regulation is important for the TGF-β
response in PDAC. Interestingly, the correlations between both
miRNAs with let-7a in clinical samples with low LIN28B levels
are much weaker than the correlation between miR-125b and
miR-100 themselves. This may be because identical let-7a
sequences are produced from three different genomic locations
that may be differentially regulated in different PDACs, thereby
affecting correlation with members of MIR100HG lncRNA.
Alternatively, other known or unknown let-7a post-transcrip-
tional regulators maybe differentially expressed in tumor speci-
mens affecting these correlations.
To ﬁnd and characterize targets regulated by these miRNAs, we
introduced a novel method based on ectopic modulation of
miRNAs in cultured cells, followed by integration of AGO2-RIP-
seq, RNA-seq, and sequence enrichment analysis, which we called
RIP-USE. Although AGO2-RIP-seq has previously been used to
identify miRNA targets43 this method has never integrated RNA-
seq with a detailed motif enrichment analysis, followed by
cumulative distribution for validation of discovered
miRNA–target interactions. RIP-USE can be applied to even
poorly expressed miRNAs and for multiple cell lines, because it is
based on ectopic modulation of the miRNA of choice, identifying
targets that are also down-regulated. We propose that the inte-
gration of RNA-seq within this method would permit to statis-
tically test the validity of canonical/noncanonical-mediated
repression by performing cumulative distribution analyses.
Importantly, RIP-USE, supported by a CLASH study42, indicates
that miR-100 uses AGO2 to regulate a much higher number of
targets than the few that have complementary canonical or
noncanonical seeds in their 3′UTRs, even without interacting
with deﬁned complementary sites in their seed regions.
Following activation by TGF-β, miR-100, and miR-125b target
and down-regulate several genes belonging to the same pathways,
which are all important during PDAC progression (Fig. 8). We
hypothesize that the concurrent inhibition of these transcripts, by
these two miRNAs, confers robustness to the TGF-β regulated
processes. IPA analysis of the targets shows that both miR-125b
and miR-100 signiﬁcantly inhibit p53 signaling and apoptosis.
Accordingly, we demonstrate that antagonizing both miRNAs
increases sensitivity to GEM promoting apoptosis, therefore
suggesting the potential usefulness of this as a clinical strategy to
enhance GEM activity in PDAC.
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Genes that are up- and down-regulated by these two miRNAs
seem to be involved in a remarkable number of common
pathways (Fig. 8). IPA Z-score values indicate that they both
down-regulate genes and pathways normally associated with
good cancer prognosis, such as p53, PTEN, and p38 MAPK
signaling44, and conversely up-regulate oncogenic and metastatic
signaling such as PI3K/AKT and actin nucleation by ARP–WASP
complex.
In summary, we describe here that miR-100 and miR-125b are
both induced in PDAC by TGF-β signaling and cooperate to
regulate similar pathways to promote stemness, EMT and
tumourigenesis (Fig. 8). We propose that either single or con-
current inhibition of these miRNAs in conjunction with GEM
could be considered as a potential adjuvant strategy for control-
ling PDAC, especially if patients have tumors overexpressing
these miRNAs.
Methods
Cell culture. BxPC-3, PANC-1, and COLO357 cells were obtained from American
Type Culture Collection. S2-007 and S2-028 cells were obtained from Prof. Thomas
Gress (University Hospital Marburg, Marburg, Germany). PANC-1 stably
expressing TGF-β1 or empty vector were obtained from Prof Matthias Löhr and Dr
Rainer Heuchel (Karolinska University Hospital, Stockholm, Sweden). CHX45 cells
were obtained from Dr Bruno Sainz Jr (Department of Biochemistry, Universidad
Autónoma de Madrid, Madrid, Spain)33. BxPC-3, COLO357, CHX45 and the two
primary cell cultures from PDAC patients (LPC006 and LPC167)45 were grown in
RPMI-1640 medium supplemented with 10% fetal calf serum, 2 mM L-glutamine,
100 U ml−1 penicillin, and 100 mg ml−1 streptomycin. PANC-1, S2-007, and S2-
028 were maintained in Dulbecco’s modiﬁed Eagle medium supplemented with
10% fetal calf serum, 2 mM L-glutamine, 100 U ml−1 penicillin, and 100 mg ml−1
streptomycin. PANC-1 and S2-007 stable miRZip lines were expanded in pur-
omycin (Gibco). All cells lines were tested monthly for mycoplasma contamination
(MycoAlert, Lonza).
Transfections and cell treatments. Mimics, inhibitors, and Silencer Select siR-
NAs were purchased from Ambion. Mimics and inhibitors were transfected into
cells using HiPerFect Transfection Reagent (Qiagen, Crawley, UK) whilst Silencer
Select siRNAs were transfected using Lipofectamine RNAiMAX (Invitrogen) fol-
lowing the manufacturer’s recommended protocol. Unless otherwise speciﬁed 5
nM of mimics, 100 nM of anti-miRs or 40 nM of siRNAs were transfected for 48 h.
For experiments of siRNA co-transfection, 20 nM of each siRNA was used. Mimics:
negative control #1 mimic (AM17110), pre-miR-100 (PM10188), pre-miR-125b
(PM10148). Inhibitors: anti-miR negative control #1 (AM17010), anti-miR-100
(AM10188), anti-miR-125b (AM10148). siRNAs: negative control #2 (4390846),
siLIN28B (4392420 s52479), siSMAD2 (4392420 s8397), siSMAD3
(4392420 s8400). For experiments of miRNA overexpression for 12 days, cells were
transfected with the miRNA mimics (5 nM) and every 3 days cells were split and
re-transfected with additional miRNAs mimics. For TGF-β treatments, PANC-1
cells were treated with 5 nM TGF-β (R&D Systems) for the indicated time.
SB431542 (Sigma) was used at 2.5 μg ml−1 in combination with TGF-β for 24 h.
Gemcitabine (GEM) was used at 1 µM for 24 h.
Generation of miR-Zip stable lines. PANC-1 and S2-007 miR-100 and miR-125b
knockdown stable lines were generated using miRZipTM lentivector-based anti-
microRNAs technology (System Biosciences), following the manufacturer’s pro-
tocol. miRZip lentiviral vectors stably inhibit the miRNA of interest by expressing a
single-stranded shRNA which is recognized by DICER and processed to generate
functional anti-miRNAs for the target miRNA. miRZip100 (Cat# MZIP100-PA-1),
miRZip125b (Cat# MZIP125b-PA-1) or miRZip control (Cat# MZIP000-PA-1)
were packaged using the pPACKH1 lentivector packaging kit (LV500A-1, SBI) in
293TN produced line (LV900A-1, SBI) and transduced into PANC-1 or S2-007
cells. Cells were selected using puromycin (1.6 µg ml−1) for 7 days. The selected
pool was then subjected to FACS sorting for GFP expression and 1 cell per well was
seeded in a 96 well plate. Clones were left to grow and subsequently screened using
the Cells-to-Cts protocol followed by QuantiMir RT kit (RA420A-1, SBI) using
custom designed probes for Zip-100 and Zip-125b. The clones with the highest
Zip-100 or Zip-125b expression were selected for phenotypic experiments. For
in vivo metastasis assay S2-007 clones were transduced with lentiviral particles
carrying red-shifted Luciola italica luciferase transgene (RediFect Red-Fluc-Pur-
omycin, PerkinElmer). To assess the effect of TGF-β in vivo when miR-100 or
miR-125b are inhibited, PANC-1 miR-100 Zip and miR-125b Zip clones were
stably transduced with a lentiviral vector carrying TGFB-1 ORF (Cat# EX-Z5895-
Lv151, GeneCopoeiaTM) or vector control (Cat# EX-NEG-Lv151, GeneCo-
poeiaTM). Cells were selected using G418 (800 µg ml−1) for 7 days.
CRISPR-Cas9-mediated KO lines. All sgRNAs used for CRISPR-mediated
PANC-1 KO lines were designed using the CRISPR design tool (http://crispr.mit.
edu/). To generate mir-100 and mir-125b KO clones, pairs of sgRNAs were chosen
within the miRNA genomic locus (see Fig. 4a) with the aim of disrupting part or
the entire miRNA locus. For deletion of MIR100HG promoter region
(MIR100HGΔP), pairs of sgRNAs were chosen to remove the SMAD2/3 peaks
predicted by MACS2 from our ChIP-seq experiments. Finally, to generate LIN28B
KO clones a single sgRNA targeting the genomic region downstream of the AUG
translation start site codon was used. Oligonucleotides containing sgRNA
sequences were cloned into lentiCRISPRv2 vector (a gift from Feng Zhang;
Addgene #5296146) following the lentiCRISPRv2 and lentiGuide oligo cloning
protocol deposited by the Zhang lab on Addgene. Oligonucleotides sequences are
provided in Table 1. For LIN28B, miR-100 and miR-125b KO clones, lenti-
CRISPRv2 containing the target sgRNA sequences were transfected in PANC-1
cells using Lipofectamine LTX (Invitrogen). At 24 h post-transfection, medium was
replaced and cells were selected with 10 μg mL−1 of puromycin (Gibco). After 48 h
of antibiotic selection cells were left to grow and validation of CRISPR-Cas9
genome editing was assessed by Sanger sequencing of the PCR products of interest.
Primers used for PCR ampliﬁcation of genomic loci edited by CRISPR-Cas9 are
indicated in Table 2. Cells with the desire genome editing were FACS sorted into 96
well plates as single cells and clones were left to grow for 7 days. Selected clones
were further validated by Sanger sequencing and KO of the gene of interest was
conﬁrmed by RT-qPCR in case of miR-100 and miR-125b or western blot for
LIN28B. The MIR100HGΔP line was generated by lentiviral infection in PANC-1
cells. Brieﬂy, lentiCRISPRv2 containing the target sgRNA sequences were co-
transfected with packaging plasmids pMD2.G and psPAX2 (both gifts from Didier
Trono; Addgene plasmids #12259 and #12260) in HEK293T cells using Lipo-
fectamine LTX (Invitrogen). Medium was refreshed after 8 h and lentivirus-
containing medium was collected 60 h after transfection. PANC-1 cells were
infected with lentivirus supernatant supplemented with 8 μg ml−1 polybrene
(Sigma). At 24 h post-infection medium was refreshed and cells were selected with
10 μg mL−1 of puromycin for 48 h. Cells were left to grow and deletion of the
promoter region was conﬁrmed by Sanger sequencing.
RNA isolation and RT-qPCR assays. Total RNA from cultured cells was extracted
using TRI Reagent (Sigma) following the manufacturer’s instructions including
DNase I treatment. qRT-PCR of mature miRNAs was performed using TaqMan
Small RNA Assays (Applied Biosystems) with assays for hsa-miR-100 (000437),
hsa-miR-125b (000449), hsa-let-7a (000377), has-miR-200a (000502). Small
nuclear RNA U44 (001094), U47 (001223), or U6 (001973) were used as endo-
genous controls. For gene expression, cDNA was synthesized from 1 μg of puriﬁed
DNase-treated RNA using RevertAidTM M-MuLV reverse transcriptase and ran-
dom hexamer primers (Thermo Scientiﬁc), according to the manufacturer’s pro-
tocols. We performed qRT-PCR on a StepOne™ Real-Time PCR System using Fast
SYBR® Green Master Mix (both from Applied Biosystems). The primer sequences
used are reported in Table 2.
Sphere formation assay. BxPC-3, PANC-1, PANC-1 ZiP stable lines, PANC-1
CRISPR-Cas9 KO lines or PANC-1 TGF-β stables were plated as single cell sus-
pension in 6 well ultra-low attachment plates (Corning) at a density of 2 × 103 cells/
well. Cells were grown in serum free DMEM/F12 medium (Gibco) supplemented
with B27 (1:50, Gibco) and 20 ng ml−1 basic ﬁbroblast grown factor (bFGF, Bio-
legend). Tumor spheres were counted at day 7 when typically reached a size of >75
μm. Sphere formation efﬁciency (SFE) was calculated as the number of spheres
formed at day 7 divided by the number of cells seeded and expressed as a
percentage.
Table 1 Oligonucleotides for sgRNA cloning
sgRNA Sequence
mir-100 sgRNA1-F CACCGATCTACGGGTTTGTGGCAAC
mir-100 sgRNA1-R AAACGTTGCCACAAACCCGTAGATC
mir-100 sgRNA2-F CACCGTTAGGCAATCTCACGGACC
mir-100 sgRNA2-R AAACGGTCCGTGAGATTGCCTAAC
mir-125b sgRNA1-F CACCGACCGTTTAAATCCACGGGTT
mir-125b sgRNA1-R AAACAACCCGTGGATTTAAACGGTC
mir-125b sgRNA2-F CACCGCGAGTCGTGCTTTTGCATCC
mir-125b sgRNA2-R AAACGGATGCAAAAGCACGACTCGC
MIR100HGΔP sgRNA1-F CACCGCAAGAGTGTAAAGACCCCGA
MIR100HGΔP sgRNA1-R AAACTCGGGGTCTTTACACTCTTGC
MIR100HGΔP sgRNA2-F CACCGGAGCATACGTGTCCCCATC
MIR100HGΔP sgRNA2-R AAACGATGGGGACACGTATGCTCC
LIN28B sgRNA-F CACCGCCGTGGGGCAACATGGCCGA
LIN28bB sgRNA-R AAACTCGGCCATGTTGCCCCACGGC
The 20 bp sgRNA sequence is highlighted in bold
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Western blotting. Whole cell lysates were prepared in RIPA buffer (Sigma) and
quantiﬁed using Bradford Protein Assay (Bio-Rad). Twenty micrograms of lysates
were resolved on Bolt® 4–12% Bis-Tris Plus gels using BoltTM MOPS SDS Running
buffer and transferred to a Hybond C super nitrocellulose membrane (GE
Healthcare). After blocking to prevent non-speciﬁc binding in 5% milk in PBST for
1 h at room temperature, membranes were incubated with the speciﬁc primary
antibodies overnight at 4 °C. The following primary antibodies were used: E-
cadherin (Takara Bio Inc., M106, clone HECD-1, 1:1000 dilution), Occludin (Cell
Signaling, #5446, 1:1000 dilution), Vimentin (Cell Signaling, #5741, 1:3000 dilu-
tion), ZEB1 (Santa Cruz, sc-25388, 1:500 dilution), SNAI1 (Santa Cruz, sc-28199,
1:500 dilution), LIN28B (Cell Signaling, #4196, 1:1000 dilution), LIN28A (Cell
Signaling, #3978, 1:1000 dilution), SMAD2/3 (Cell Signaling, #8685, 1:1000 dilu-
tion), β-actin (Abcam, ab8227, 1:200,000 dilution), GAPDH (Santa Cruz, sc-
137179, 1:10,000 dilution). Following incubation with the speciﬁc HRP-conjugated
antibody (Dako, #P0447 or #P0448, 1:2,500 dilution), chemiluminescence signal
was detected using AmershamTM ECLTM Western blotting detection reagents (GE
Healthcare) and Amersham HyperﬁlmTM ECL (GE Healthcare). Uncropped scans
of the most important blots are shown in Supplementary Fig. 13.
Immunoﬂuorescence staining. Cells grown on glass coverslips were ﬁxed in 4%
paraformaldehyde for 10 min at room temperature. Cells were washed twice with
PBS (15 min each) and permeabilised with 0.3% (v/v) Triton X-100 for 10 min.
Blocking buffer (1% w/v BSA, 2% v/v FCS, 5% v/v goat serum in PBS) was added
for 30 min and cells were then stained with anti-E-cadherin antibody (Takara Bio
Inc., M106, clone HECD-1, 1:1000 dilution) and Alexa Fluor® 555 (Invitrogen, A-
21422, 1:500 dilution). F-actin was detected with phalloidin-Alexa Fluor 488®
(Invitrogen, A12379, 1:500 dilution) and nuclei were visualized using TO-PRO®-3
(Invitrogen, T3605, 1:1000 dilution). Images were acquired with a Zeiss LSM 510
META confocal microscope (Carl Zeiss Ltd).
Wound-healing migration assays. Conﬂuent cells were scratch-wounded using a
20 μl pipette tip and cell debris were removed by washing with PBS. Phase-contrast
images were taken at the indicated time points at speciﬁc wound sites using EVOS
microscope with a 10 × objective. For time-lapse experiments, cell migration was
assessed by phase-contrast videomicroscopy with sequences taken every 30 min for
24 h after scratching using Axiovert 100 MetaMorph Microscope (Carl Zeiss Ltd)
ﬁtted with a humidiﬁed 37 °C incubation chamber. For wound-healing assay in
adenocarcinoma primary lines LPC006 and LPC067, cells were transfected with
100 nM of anti-miR-NC, anti-miR-100 or anti-miR-125b and seeded in 96 well
plates (30 × 104 cells/well), where artiﬁcial wounds were made using a pipette tip.
The ability of the cells to migrate was evaluated by comparing the pixels of the
wound tracks in the images taken at the beginning of the exposure (time 0) with
those taken 2 hourly for 8 h and then ﬁnally at 16 h. Migration was assessed using
the LeicaDMI300B (Leica) migration station integrated with the Scratch-Assay
6.1 software (Digital-Cell Imaging Labs, Keerbergen, Belgium).
Flow cytometry. To identify CD133 positive population, 1 × 106 S2-007 Zip cells
were trypsinized, washed with PBS and stained with antiCD133/1-APC (Miltenyi
Biotec) or appropriate isotype-matched control antibody for 30 min at 4 °C. The
labelled cells were washed in PBS and subjected to ﬂow cytometry on a FACS
Canto II (BD Bioscieces). Data were analyzed with FlowJo v8.8.9 software.
Apoptosis assay. LPC006 and LPC067 cells were transfected with 100 nM of anti-
miR-NC, anti-miR-100, or anti-miR-125b and the next day were treated with 1 µM
gemcitabine (GEM) chemotherapy for 24 h. Following treatments, cells were
washed twice with PBS and ﬁxed in 4% PFA for 15 min. Cells were then resus-
pended in a solution containing 8 μg ml−1 bisbenzimide HCl and incubated for 15
min. Cells were spotted on glass slides and were examined by ﬂuorescence
microscopy (Leica, Wetzlar, Germany). A total of 200 cells from randomly chosen
microscopic ﬁelds were counted, and the percentage of cells displaying chromatin
condensation and nuclear fragmentation relative to the total number of counted
cells (apoptotic index) was calculated. The average percentage of apoptosis induced
by GEM and anti-miR-NC (negative control) was 19% and 12% in the LPC006 and
LPC067 cells, respectively. These values were set as 100%, in order to show the
difference after treating with the other anti-miRs more clearly. Apoptosis induction
<20% indicates that both cell lines are not very sensitive to GEM.
Luciferase reporter assays. PANC-1 cells were seeded onto 24 well plates at a
density of 50 × 104 cells/well in antibiotic-free medium. Twenty-four hours later,
cells were co-transfected with pre-miR-100 or pre-miR-125b or negative control
(100 nM) together with the 3’UTR of relevant genes reporter constructs
(pLightSwitch_3UTR GoClone vectors, SwitchGear Genomics) at 100 ng/well
using Lipofectamine2000 (Invitrogen). After 24 h, cells were washed with PBS and
50 μl of passive lysis buffer (Promega) was added to each well. After a 20-min
incubation lysates were transferred to an optical quality 96 well plate (OptiPlate,
PerkinElmer) and luciferase activity was measured using the LightSwitch Assay
System (SwitchGear Genomics) as directed by the manufacturer. The resulted light
emission was read using the Inﬁnite M200 plate reader (Tecan) and the mean
luciferase activity for each precursor miRNA is shown relative to the mean for the
negative control.
miRNA nCounter proﬁling. The Nanostring nCounter Human miRNA Expres-
sion Array (http://www.nanostring.com/) was used to obtain miRNA expression
proﬁles47. nCounter miRNA sample preparation was performed according to the
manufacturer’s instructions (NanoString Technologies). Differential expression
analysis between different cell lines and PANC-1 cells treated with TGF-β or
vehicle was performed in R, using nCounter raw values as input for DESeq2
analysis (http://bioconductor.org/packages/release/bioc/html/DESeq2.html).
AGO2 RNA immunoprecipitation. PANC-1 cells were seeded in 15 cm dishes
(5 × 106 cells/dish; 3 dishes were used for each antibody tested) and transfected
with 0.5 nM of pre-NC, pre-miR-100 and pre-miR-125b for 24 h. AGO2-RIP was
carried out as previously described by our group48. Brieﬂy, following transfection
cells were washed in cold PBS, scraped in PBS and collected by centrifugation.
Pellets were then resuspended in lysis buffer (20 mM Tris-HCl pH7.5, 150 mM
KCl, 0.5% NP40, 2 mM EDTA, 1 mM NaF, 0.5 mM DTT, 160 U ml−1 RNAsin and
protease and phosphates inhibitors) and pre-cleared with Protein G sepharose
beads (Sigma) for 2 h at 4°C. Part of cleared lysates (10%) was used as input and the
remainder were incubated with Protein G sepharose beads conjugated with anti-
AGO2 (11A9, SAB4200085, Sigma-Aldrich) or anti-IgG (Sigma-Aldrich) for 4 h at
4°C. After washing, 10 μl of the immunoprecipitate was kept for western blot
analysis and the remainder was treated with DNAse I and proteinase K for 20 min
at room temperature. RNA was extracted using phenol/ chloroform and and
ethanol/sodium acetate precipitation. RNA was then quantiﬁed using Nanodrop.
Chromatin immunoprecipitation. PANC-1 cells were treated with 5 nM TGF-β
for 24 h and chromatin immunoprecipitation (ChIP) was performed as follows49:
brieﬂy cells were crosslinked with 1% formaldehyde, chromatin was prepared and
incubated with 10 µg of SMAD2/3 antibody (R&D, AF3797) and 100 µl of Dyna-
beads Protein A (10002D; Invitrogen) overnight at 4°C. The immune-precipitated
Table 2 PCR primers used in this study
Primer Sequence
miR-100 genomic-F AAAGTGGAAACCAAGGGAAGCAC
miR-100 genomic-R CTCATTCATTTCAGGACAAAAGGTC
miR-125b genomic-F GAAGAAATACCATACCACCTGTT
miR-125b genomic-R GTCACCTGATCCCATCTAACAAT
LIN28B genomic-F TAGATTGATGCAGAAGATCACTCC
LIN28B genomic-R AAGTTGTGAATCAGTGTGGG
MIR100HGΔP genomic-F TTTCCATGTAAGAATGGTCTCC
MIR100HGΔP genomic-R TTCATTCTATTTCCTGAAGCTGGG
pre-miR-100-F AACCCGTAGATCCGAACTTG
pre-miR-100-R TACCTATAGATACAAGCTTGTGCG
pre-miR-125b-F GTCCCTGAGACCCTAACTTG
pre-miR-125b-R AGCCTAACCCGTGGATTT
LIN28B-F TTAGGAAGTGAAAGAAGACCCA
LIN28B-R ACCACAGTTGTAGCATCTATCT
CDH1-F CCCACCACGTACAAGGGTC
CDH1-R CTGGGGTATTGGGGGCATC
SNAI1-F GAGGCGGTGGCAGACTAG
SNAI1-R GACACATCGGTCAGACCAG
CD133-F TCGACAATGTAACTCAGCGT
CD133-R CCCAGCCACCAGTATGAAT
ANKRD28-F GGACATGGTGAGATGGTCAA
ANKRD28-R CCAATGGATAGCACGCCT
CPEB2-F GAGCAGAGCATGATCCTCTT
CPEB2-R AGAGGGAAGAACGACCATTT
PXN-F CCCATCCTGGATAAAGTGGT
PXN-R GCACAGAAGAAGTGTTCAGG
NF2-F TCCAGCTATGTATCGGGAAC
NF2-R CCGCTCCATCTGCTTTCTA
NUMB-F CCAGTCGTCCACATCAGT
NUMB-R ACAGATGTGCATTCCTCTTGA
MIR100HG-F ACACAGACTTGTCTTTGGACA
MIR100HG-R AAACCTGCTTCCATCTTGTTAG
U6-F CTCGCTTCGGCAGCACA
U6-R AACGCTTCACGAATTTGCGT
GAPDH-F TGAAGGTCGGAGTCAACGGATTT
GAPDH-R GCCATGGAATTTGCCATGGGTGG
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complex was washed with RIPA buffer and TE buffer, followed by de-crosslinking
for 16 h. DNA was then treated with RNase and Proteinase K at 1 mg ml−1 and
puriﬁed with phenol-chloroform and sodium chloride precipitation. For ChIP-PCR
the primer sequences are as follow: SNAI1 (Forward: 5’-CGCTCCGTAAA-
CACTGGAT-3’; Reverse: 5’-GAAGCGAGGAAAGGGACAC-3’), MIR100HG
(Forward: 5’-AGCAAACACATTTCAGGCAGT-3’; Reverse: 5’-GGCTACCT-
GACTGATGAGTG-3’), HBB (Forward: 5’-GCTTCTGACACAACTGTGTTCAC-
3’; Reverse: 5’-CACCAACTTCATCCACGTTCACC-3’).
ChIP-seq library preparation and bioinformatics analysis. ChIP-seq libraries
were constructed using NEBNext Ultra II DNA library prep kit for Illumina kit
(NEB), according to the manufacturer’s protocols. Ten nanograms of DNA was
used for library preparation. Single-end reads of 50 nt in length were generated
using a HiSeq 2000 instrument (Illumina). Sequences were aligned to the human
reference genome (assembly hg19, February 2009) using Bowtie 1.0. and peak
calling was performed using MACS v1.4 using default settings. ChIP-seq data of
CTCF, H3K4me3, and H3K27ac from PANC-1 or Pancreata were obtained from
ENCODE and plotted using IGV genome browser.
Hi-C analyses. Hi-C data of PANC-1 comes from ENCODE. Analyses and graphs
were performed using online tools from http://promoter.bx.psu.edu/hi-c/.
RNA-seq and AGO2-RIP-seq library preparation. RNA libraries for RNA-seq
and AGO2-RIP-seq were prepared with TruSeq RNA Library Prep Kit v2 (Illu-
mina), according to the manufacturer’s protocols. Paired-end sequences (reads) of
100 nt in length were then generated using a HiSeq 2000 instrument (Illumina).
Processing of RNA-seq and AGO2-RIP-seq data. The quality of the reads
contained in the fastq ﬁles obtained at the end of the sequencing was assessed using
FastQC version 0.10.1 (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/
). The reads from the fastq ﬁles, for each sample, were then mapped on the
reference human genome, version hg19, obtained from the University of California
Santa Cruz (UCSC) genome browser (https://genome.ucsc.edu/) by using TopHat.
For isoform level analysis (miRNA target identiﬁcation) RPKM normalized values
were produced with Partek Genomic Suit software (Partek Inc) using the bam ﬁles
attained after the TopHat runs, as input. For gene level analysis (TGF-β treatment)
raw counts were produced using htseq version 0.6.1 (http://www-huber.embl.de/
HTSeq/) with human RefSeq annotation and used for differential expression
analysis with DESeq2 from the Bioconductor (https://www.bioconductor.org/).
RIP followed by Unbiased Sequence Enrichment (RIP-USE). We developed RIP-
USE for miRNA-target identiﬁcation in order to identify canonical and non-
canonical targets for miR-100 and miR-125b. It integrates AGO2-RIP-seq with
RNA-seq and unbiased motif enrichment analysis to identify enriched motifs
complementary to any part of the miRNAs enriched in the transcripts loaded onto
AGO2 upon expression of miR-125b or miR-100 in cell lines. The function of
these motifs in regulating targets through miRNA interaction was then tested by
performing cumulative distribution analyses comparing the global expression of
transcripts containing identiﬁed sites versus transcripts without them, upon
miRNA expression. It consists of different steps (Fig. 6a): (1) miRNA over-
expression in cell lines, (2) AGO2-RIP-seq of the cells overexpressing the miRNA
of interest or a negative control (n.c.), (3) RNA-seq of the cells overexpressing the
miRNA of interest or a negative control (n.c.). After mapping of the sequencing
reads followed by gene expression analysis (4) the transcripts are then sorted from
the most enriched to the least enriched in AGO2 for AGO2-RIP-seq, as well as
from the least down-regulated to most up-regulated for RNA-seq. Considering that
usually the region of the miRNAs that base pairs with their targets correspond to a
6–8 mer located in the 5’ part called the ‘seed’50 the genes enriched for AGO2 and
the ones down-regulated after the expression of the miRNA of interest should be
enriched of words 6–8 bases long complementary (canonical pairing) or partly
complementary (noncanonical pairing) with the seed of the overexpressed miR-
NAs. Considering this principle, (5) to ﬁnd bona ﬁde targets of the overexpressed
miRNAs we used tools that unbiasedly retrieve enriched words 6–8 bases long
within selected regions of sorted transcripts38,40,51 for both AGO2-RIP and RNA-
seq. We evaluated whether (6) words representing noncanonical interaction
derived from regions of enriched transcripts onto AGO2 for RIP-seq overlap with
the ones from regions of down-regulated transcripts for RNA-seq. Finally (7) we
validated whether the transcripts containing these 6–8mers are actually regulated
by the miRNAs, evaluating whether transcripts containing those words were sig-
niﬁcantly down-regulated compared to transcripts without those words in RNA-
seq upon the overexpression of the miRNAs, using cumulative distribution analysis
(Fig. 6b,c).
Pathway analyses. Pathway analyses were performed using IPA (Qiagen, http://
www.ingenuity.com/products/ipa). Genes from the overlap between the most
enriched transcripts in AGO2-RIP-seq (n= 4000) and the top down-regulated
transcripts in RNA-seq (1300) were used as gene sets for the analysis (Fig. 7a,b).
Expression values (Log2FC) were also including to obtain the IPA Z-score that
infers onto activation (positive Z score) or inhibition (negative Z score) of the
signiﬁcant enriched pathways. Networks of top enriched IPA pathways were built
using Cytoscape software v3.4 (http://www.cytoscape.org/). For IPA comparison
analysis, genes that were up and down-regulated (Z-score > 1.5 and Z-score <−1.5)
were analyzed.
Analysis of mRNA and miRNA expression proﬁling from The Cancer Genome
Atlas (TCGA) database. Level 3 data of miRNA and mRNA expression proﬁling
data from pancreatic adenocarcinoma samples (PPAD-TCGA) were downloaded
from the TCGA database (https://portal.gdc.cancer.gov/projects/TCGA-PAAD)
and used to develop gene and miRNA expression matrices. Pearson correlation
analyses between miRNAs as well as between miRNAs and mRNAs of interest were
calculated and graphed using R (https://www.r-project.org/). We considered low
LIN28B level samples to be those that express less than 0.5 RSMEs (https://
bmcbioinformatics.biomedcentral.com/articles/10.1186/1471-2105-12-323).
In vivo tumorigenicity and metastasis assays. For tumorigenesis assays, serial
dilutions of S2-007 Zip cells diluted in 50 μl PBS were injected subcutaneously in
both ﬂanks of 4- to 5-week-old female athymic nude mice (Charles River
Laboratories). Control cells were inoculated to the right ﬂank and Zip100 or
Zip125b cells to the left. Tumor growth was documented for 3 weeks. For TGF-β
tumorigenesis assay, 2 × 106 PANC-1 Zip cells stably expressing TGF-β1 or empty
vector diluted in 50 μl PBS were injected subcutaneously in both ﬂanks of 4- to 5-
week-old female athymic nude mice (Charles River Laboratories). Tumor growth
was documented for 5 weeks. For metastasis assay, 25 × 104 S2-007 Zip cells stably
expressing luciferase resuspended in 50 μl PBS were intrasplenically injected into 4-
to 5-week-old female athymic nude mice (Charles River Laboratories). Seven days
after injection the spleen was removed to avid growth of the tumor at the injection
site. Tumor dissemination was monitored twice a week for 3 weeks by biolumi-
nescence imaging using the IVIS Spectrum Imaging System (Caliper Life Sciences).
Brieﬂy, mice were injected intraperitoneally with 150 mg kg−1 of luciferin (Pro-
mega, E1605) diluted at 15 mgmL−1 in sterile PBS and imaged after ~15 min. The
Living Image Software (Caliper Life Sciences) was used to quantify photon emis-
sion and regions of interest (ROI) was used to calculate the total photons/second
(photons ﬂux) emitted. The number of animals used in all experiments reﬂected
the expected magnitude of response taking into account the variability observed in
previous experiments. Mice were randomly allocated to each group. Investigators
were not blinded. Animal experimental procedures were conducted under the UK
Home Ofﬁce Project License number PPL 70/8448.
Laser capture microdissection (LCM) of tissues. Samples of matched tissues
(normal pancreas, n= 8; PDAC, n= 20; lymph-node metastasis, n= 20) were
obtained from FFPE blocks of surgical specimens after pancreaticoduodenectomy
(all resectable Stage IIB) at Hammersmith Hospital, UK. Cells were selectively
isolated with the PALM laser capture microdissection (LCM) platform (Carl Zeiss
Ltd., Cambridge, UK) according to the manufacturer’s protocols. This was per-
formed to allow conﬁrmation of cell-type speciﬁc changes in miRNA expression52.
Total RNA was subsequently extracted using the RNeasy FFPE Kit (Qiagen, Hil-
den, Germany) following the manufacturer’s protocol. Informed consent was
obtained from all patients and ethical approval was received from the Camden &
Islington REC, London (09/H0722/77) in the UK.
LNA-based microRNA in situ hybridization. Patients: The aim of this experiment
was to study expression of miR-100 and miR-125b in human PDAC tissue samples
by LNA-based miRNA ISH. The experiment included formalin-ﬁxed parafﬁn
embedded (FFPE) tumor specimens from 100 PDAC patients (all resectable Stage
IIB) arranged on 4 tissue-microarrays (TMA), each containing 25 patient sample.
For each patient tumor there were 4 cores (1.5 mm diameter) in order to avoid
intra-tumoral heterogeneity and best represent the tumor. Hematoxylin and eosin
(H&E) staining was performed on all samples prior to processing for the ISH
analysis in order to conﬁrm tumor histology. Patients underwent surgery for
PDAC at the University of Pisa, Italy during 2005–2010 and were closely followed-
up. None of the patients received neo-adjuvant chemotherapy, but all received
adjuvant chemotherapy. Complete clinicopathological, follow-up and recurrence
data were available from a prospectively maintained database.
LNA probes: DNA oligonucleotides with approximately 30% Locked Nucleic
Acid (LNA) substitutions53 for the full length miRNA were used: miR-100-5p
(predicted Tm ~ 85 °C; target sequence CACAAGTTCGGATCTACGGGTT; 32%
LNA) and miR-125b-5p (predicted Tm ~ 85 °C; target sequence
TCACAAGTTAGGGTCTCAGGGA; 27% LNA) (Exiqon, Vedbaek, Denmark). In
addition, a probe speciﬁc for U6 snRNA (ACGAATTTGCGTGTCATCCTT;
predicted Tm ~ 83 °C; 29% LNA) was used as positive control, and a 21-mer
scrambled probe with a random sequence (TGTAACACGTCTATACGCCCA;
predicted Tm ~ 87 °C; 33% LNA) having no known complementary sequence
target among human transcripts performing MegaBLAST search at NCBI
GenBank, was included as negative control (Exiqon, Vedbaek, Denmark). All LNA
oligos were digoxigenin (DIG)-labeled at the 5′- and 3′-ends except the U6 probe,
which was only 5′-end labeled.
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In situ hybridization: Five μm-thick parafﬁn TMA sections were mounted on
Super frost+ glass slides and deparafﬁnized. ISH for miRNA detection was carried
out using a miRCURY LNA miRNA ISH kit (Exiqon, Vedbaek, Denmark) as
previously described54 with few modiﬁcations. For optimization, miR-100 and
miR-125b probe concentrations and proteolytic pre-treatment were evaluated on
4 separate full-size FFPE PDAC sections. A proteinase-K (PK) pre-treatment of 20
μg ml−1 and probe concentration of 30 nM were chosen for subsequent TMA
analyses.
Image analysis and quantiﬁcation: Images were acquired using a 20 × and
40 × objectives with a Zeiss AxioScan. For miRNA quantiﬁcation, the following
histologically stained structures were differentiated: blue areas corresponding to the
hybridization signal, red area corresponding to the red nuclear stain, purple areas
corresponding to blue ISH signal overlaying nuclear red stain. Scoring of ISH was
performed semi-quantitatively based on staining intensity: 0, absent; 1+, weak
(visible at 200 ×magniﬁcation); 2+, moderate (visible at 100 ×magniﬁcation); 3+,
strong (visible at 40 × magniﬁcation). In addition, localization of miRNA signal in
either the tumoral and stromal compartments was assessed. Thus, 3 parameters
were obtained from image analysis and reﬂecting relative miRNA expression levels
were considered: (1) the stained area, (2) the staining intensity and (3) the number
of positive cells. This tissue slide-based miRNA ISH therefore provided qualitative
(tumor compartment) and semi-quantitative (expression levels) data.
Semi-quantitative ISH score: In order to accurately describe the extent of ISH
staining of a tumor core, the degree of ISH staining in each compartment (tumor
or stromal cells) was measured for each miRNA. We captured the percentage of
cells stained at each intensity level and then used an intensity scale ranging from 0
for no staining, to 3+ for the most intense staining. This information was used to
calculate a variable ISH Score, more continuous than simply positive versus
negative. This ISH score for each patient tumor or stromal compartment was
calculated using the mean intensity plus % of cells of the 4 cores. The mean ISH
score for all patients was then used to dichotomize patient cores into those with
high or low miRNA expression in the cellular compartments.
Statistical analysis: MiRNA levels in tumor and stromal compartments were
compared with the Student’s t-test (2-tailed). Patients dying from PDAC after
surgical resection were considered as “death events” and this was used to calculate
the OS analysis. Date of death was obtained from the hospital records, family
doctor or Italian Civil Registration. Patients who were categorized as having an
event in the calculation of DFS experienced local tumor recurrence in the form of
either local or distant metastasis. High and low miRNA ISH score, using the mean
value as a cut-off, was then used to associate miRNA expression with survival
outcomes following pancreaticoduodenectomy (PD) surgery (i.e. from date of
surgery to date of death, or date of disease progression). Survival curves were
constructed using the Kaplan-Meier method and differences in survival were
compared by log-rank test. All statistical analyses were done using SPSS 20.0 (IBM,
SPSS). P values ≤0.05 were considered signiﬁcant.
Data availability. The accession number for the Nanostring, RNA-seq, RIP-seq,
and ChiP-seq data reported in this paper is GEO: GSE88759. All other remaining
data are available within the Article and Supplementary Files, or available from the
authors upon request.
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